| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Administration expenses | 4,598,574 | 53,068,147 | 153,593 | 220,759 |
| Occupancy expenses - related party | 14,789 | 6,469 | 5,401 | 8,317 |
| Research and development | 60,201 | 54,097 | 54,388 | 61,714 |
| Total operating expenses | 4,673,564 | 53,128,713 | 213,382 | 290,790 |
| Derivative expense | - | 59,271 | 8,559 | 27,182 |
| Loss from operations | -4,673,564 | -53,128,713 | -213,382 | -290,790 |
| Interest expense | 305,649 | 104,042 | 118,943 | 86,230 |
| Interest income | 19 | 1 | - | 1 |
| Change in fair value of derivative liabilities | -19,706 | 47,119 | 13,581 | 52,787 |
| Gain (loss) on extinguishment of debt, net | 195,861 | -809,954 | -18,759 | -11,319 |
| Foreign currency transaction gain (loss) | -34,699 | -12,486 | -84,121 | 8,423 |
| Total other income (expense), net | -164,174 | -938,633 | -216,801 | -63,520 |
| Loss before taxes | -4,837,738 | -54,067,346 | -430,183 | -354,310 |
| Net loss | -4,837,738 | -54,067,346 | -430,183 | -354,310 |
| Net loss available to common stockholders | - | -54,067,346 | -430,183 | -354,310 |
| Unrealized foreign currency translation gain (loss) | 17,044 | -27,311 | 321,230 | -98,943 |
| Total other comprehensive income (loss) | 17,044 | -27,311 | 321,230 | -98,943 |
| Total comprehensive loss | -4,820,694 | -54,094,657 | -108,953 | -453,253 |
| Basic net loss per share | -0.39 | -12.5 | -32.23 | 0 |
| Basic weighted average shares outstanding | 12,331,526 | 4,325,994 | 13,347 | 590,937,498 |
| Diluted net loss per share | -0.39 | -12.5 | -32.23 | 0 |
| Diluted weighted average shares outstanding | 12,331,526 | 4,325,994 | 13,347 | 590,937,498 |
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. (PPCB)